Common genomic and transcriptomic signatures in Richter transformation highlight druggable vulnerabilities and guide drug repurposing strategies
Francesco Edoardo Vallone, Giulia Omezzolli, Matilde Micillo, Andrea Iannello, Giulio Ferrero, Enrico Berrino, Elisabetta Mereu, Sara Erika Bellomo, Elena Rosso, Arianna Di Napoli, Ozren Jaksic, Luca Molinaro, Caterina Marchiò, Roberto Piva, Francesca Cordero, Silvia Deaglio, Tiziana Vaisitti · 2026
Read Common genomic and transcriptomic signatures in Richter transformation highlight druggable vulnerabilities and guide drug repurposing strategies by Francesco Edoardo Vallone, Giulia Omezzolli, Matilde Micillo, Andrea Iannello, Giulio Ferrero, Enrico Berrino, Elisabetta Mereu, Sara Erika Bellomo, Elena Rosso, Arianna Di Napoli, Ozren Jaksic, Luca Molinaro, Caterina Marchiò, Roberto Piva, Francesca Cordero, Silvia Deaglio, Tiziana Vaisitti (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13421319.txt.
Description
ion (RT) is a rare and aggressive lymphoma occurring in patients with chronic lymphocytic leukemia (CLL). Despite advancements in understanding the pathogenetic mechanisms driving disease transformation, it remains a challenging malignancy [1–3]. In recent years, multi-center genomic studies have shed light on the heterogeneity of RT, with no single driver alteration identified [4–7].
Catalog record
| CREATOR | Francesco Edoardo Vallone, Giulia Omezzolli, Matilde Micillo, Andrea Iannello, Giulio Ferrero, Enrico Berrino, Elisabetta Mereu, Sara Erika Bellomo, Elena Rosso, Arianna Di Napoli, Ozren Jaksic, Luca Molinaro, Caterina Marchiò, Roberto Piva, Francesca Cordero, Silvia Deaglio, Tiziana Vaisitti |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |